Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma

This publication has 21 references indexed in Scilit:

• IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
  Journal of Clinical Oncology, 1997
• Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs
  Cancer Biotherapy & Radiopharmaceuticals, 1997
• Prognostic Factors and a Predictive Model of Follicular Lymphoma: A 25-year Study at a Single Institution in Japan
  Japanese Journal of Clinical Oncology, 1996
• Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
  The Lancet, 1995
• Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support
  New England Journal of Medicine, 1993
• Radioimmunotherapy of B-Cell Lymphoma with [¹³¹I]Anti-B1 (Anti-CD20) Antibody
  New England Journal of Medicine, 1993
• Toxicity Grading Criteria of the Japan Clinical Oncology Group
  Japanese Journal of Clinical Oncology, 1993
• Non-Hodgkin's lymphomas of follicular center cell type in Osaka, Japan
  European Journal of Cancer and Clinical Oncology, 1989
• Malignant lymphoma in Hawaii-Japanese: A retrospective morphologic survey
  Hematological Oncology, 1989
• Lymphoproliferative diseases in Japan and Western countries: Proceedings of the United States—Japan seminar, September 6 and 7, 1982, in Seattle, Washington
  Human Pathology, 1983